Clinical Trial Update: Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and efficacy of a recombinant grass pollen allergen cocktail for allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Recombinant grass pollen allergen cocktail (Recombinant grass pollen allergen cocktail)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergy | Phase 3 | Status: COMPLETED